Coherus Biosciences's total assets for Q1 2025 were $371.07M, a decrease of -17.27% from the previous quarter. CHRS total liabilities were $554.54M for the fiscal quarter, a -4.48% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.